Medical/Pharmaceuticals
POMDOCTOR LIMITED Announces First Half of Fiscal 2025 Unaudited Financial Results
GUANGZHOU, China, Dec. 3, 2025 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases inChina, today announced its unaudited financial results for the six months endedJune 30, 2025. Mr. Zhenyang Shi, Chairma...
2025-12-04 05:15
4391
ImpriMed to Present Ex Vivo Drug Sensitivity Data in Acute Myeloid Leukemia in Oral Presentation at American Society of Hematology Annual Meeting
Studies Demonstrate xCellSense® Platform's Ability to Predict Clinical Response
and Enable Patient Stratification for Drug Development.
PALO ALTO, Calif., Dec. 3, 2025 /PRNewswire/ -- ImpriMed
2025-12-04 01:00
1623
Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
* FDA approval of OMLYCLO® (omalizumab-igec) 300 mg/2 mL solution in a single-dose prefilled syringe for subcutaneous injection expands dosing flexibility and supports tailored treatment for individual patients with certain allergic diseases * OMLYCLO® (omalizumab-igec) is the first and only ...
2025-12-03 08:43
3717
Lunit to Highlight New AI Evidence in Cancer Screening and Breast Density-Driven Risk Modeling at RSNA 2025
Eight oral presentations and six posters demonstrate advances in mammography, DBT performance, and density-informed risk modeling SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, today announced it will present 14 stu...
2025-12-02 22:10
4907
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
SYDNEY, Dec. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional and accredited investors for a private placement of equity ...
2025-12-02 22:00
4694
Nature Communications | Insilico Medicine Presents AI-empowered Dual-Action PROTAC Targeting PKMYT1
* AI Designs a Novel RPOTAC from Scratch: Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its complex linker, demonstrating a powerful, end-to-end approach to new modality drug discovery. ...
2025-12-02 22:00
2928
L&C Bio's 'Re2O' Emerges as a Leading K-Medical Tour Procedure Within One Year of Launch
– Surging global demand drives rapid adoption across domestic and international medical sectors – SEONGNAM, South Korea, Dec. 2, 2025 /PRNewswire/ -- L&C Bio (KOSDAQ: 290650, Co-CEOsHwan-Chul Lee and Jae-Ho Lee), a leading company in human tissue–based regenerative medicine, announced that its p...
2025-12-02 22:00
1216
Yuyu Pharma Announces Strategic Investment in Dalan Animal Health as Part of Accelerated Global Expansion in Animal Health
SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ -- Yuyu Pharma announced today that it has completed a strategic investment in Dalan Animal Health, a U.S.-based biotechnology company advancing an innate immunity–based platform for developing vaccines for honeybees and shrimp. The investment marks a...
2025-12-02 22:00
3405
GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper
* Officially recognized by WHO as a standard varicella vaccine strain alongside Oka * Interchangeability endorsed, enhancing global supply security YONGIN, South Korea, Dec. 2, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical company, today announced that its propriet...
2025-12-02 13:00
2454
United Imaging Broadens Imaging Portfolio and Advances Native AI at RSNA 2025
The company brings a full array of technology to its two booths in Chicago, showcasing another year of increasing R&D and investment. CHICAGO, Dec. 1, 2025 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, will showcase a range ...
2025-12-02 00:00
2600
HZICC：Innovation hub: Hangzhou witness new voices and new ambitions
HANGZHOU, China, Nov. 28, 2025 /PRNewswire/ -- The remarkable achievements of past winners of Hangzhou's Innovation & Entrepreneurship Competition for Overseas Talents have set a powerful example, inspiring a new wave of international innovators to bring their projects toHangzhou. Among this yea...
2025-11-28 21:25
1868
HZICC：Unlocked potential: why global innovators choose Hangzhou
HANGZHOU, China, Nov. 28, 2025 /PRNewswire/ -- Meng Jintao, winner of the 2024 Hangzhou's Innovation & Entrepreneurship Competition for Overseas Talents, exemplifies this journey. His project on "All-Iron Redox Flow Battery Technology"--dubbed a "giant movable power bank"--has already secured let...
2025-11-28 21:19
2082
BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough
* Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyngeal carcinoma * The company enables seamless Europe–China tech transfer and faster biologics development through an integrated, end-to-end...
2025-11-28 21:00
3269
Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
* Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors. * The collaboration includes precli...
2025-11-28 13:00
1863
Keep Your Respiratory Health Strong This Season With VARON Black Friday Offers
NEW YORK, Nov. 27, 2025 /PRNewswire/ -- As the holiday season approaches,
respiratory health becomes a top priority for individuals living with chronic
conditions such as COPD, sleep apnea, or other lung diseases. VARON,
2025-11-28 06:09
1780
Strategic Partnership | Sanyou Bio and Korea's FatiAbGen Join Forces to Expand the Global Biopharma Market
SHANGHAI, Nov. 27, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") andSouth Korea's FatiAbGen Co., Ltd. today jointly announced the signing of a comprehensive strategic collaboration agreement covering joint project development, exclusive representation in the K...
2025-11-27 22:00
3210
SK Biopharmaceuticals Expands Radiopharmaceutical Therapy Portfolio with Second In-licensed Candidate from Wisconsin Alumni Research Foundation
New addition strengthens SK Biopharmaceuticals' radiopharmaceutical therapy portfolio and reinforces its R&D capabilities through global partnerships and value chain integration SEOUL, South Korea, Nov. 26, 2025 /PRNewswire/ -- SK Biopharmaceuticals, CO., Ltd., a biotech company specializing in ...
2025-11-27 10:39
1750
TCI Biotech Inaugurates Advanced Performance Nutrition Research Center, Expands Into Brain Science to Accelerate Next-Generation Health Innovation
SALT LAKE CITY, Nov. 26, 2025 /PRNewswire/ -- TCI Biotech (TCI Co., Ltd.), a global CDMO+ specializing in functional foods, nutraceuticals, and beauty supplementation, today announced the launch of the TCI Advanced Performance Nutrition Research Center, a new innovation hub focused on high-perfor...
2025-11-27 00:00
2442
Healgen Scientific Spotlights the Rapid Check® COVID-19/Flu A&B Antigen Test to Help Families Stay Prepared for the Respiratory Virus Season
HOUSTON, Nov. 26, 2025 /PRNewswire/ -- As the holiday season approaches, gatherings among family and friends are expected to increase the risk of respiratory virus transmission, including COVID-19 and influenza. In response, Healgen® Scientific highlights the Rapid Check® COVID-19/Flu A&B Antigen ...
2025-11-27 00:00
1407
Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal
* Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless of disease location, consistent across ileum-dominant and colon-dominant Crohn's disease (CD) * Findings support the therapeutic potential of ZYMFENTRA in addressing ...
2025-11-26 14:48
3798
Week's Top Stories
Most Reposted
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
The Philippines Sets a New Standard in Muslim-Friendly Tourism
[Picked up by 286 media titles]
2026-05-26 10:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 281 media titles]
2026-05-20 09:15ISDN's IDI Dynamics debuts high-speed laser marker for semiconductor assembly and test (OSAT)
[Picked up by 280 media titles]
2026-05-26 08:40
Consistently recognised: Infobip named a Leader in Gartner® Magic Quadrant™ for CPaaS again
[Picked up by 279 media titles]
2026-05-21 16:31
Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
8224
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
8004
